8 completed. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 3 | Completed 3 |
Follow Eye Abnormalities: new trials by email Literature Review of Eye Abnormalities trials Research Report on Eye Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2% - Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 3 | 2021-10-19 | 2025-01-20 |
| RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy RAFT-OS - Aniridia | Phase 1 / Phase 2 | Completed | University College, London | 9 | 2021-07-28 | 2025-04-30 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| Study of Ataluren in Participants With Nonsense Mutation Aniridia Ataluren, Placebo - Aniridia | Phase 2 | Completed | PTC Therapeutics | 39 | 2016-01-31 | 2022-05-27 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis 4 mg CLS-TA, 0.8 mg CLS-TA - Uveitis, Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 22 | 2014-10-01 | 2021-02-08 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma Latanoprost, Dorzolamide - Childhood Glaucoma | Phase 2 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 37 | 2009-07-01 | 2019-09-27 |
Choroidal Effusions (3) · Aniridia (2) · Hydrophthalmos (2) · Panuveitis (2) · Uveitis (2) · Uveitis, Intermediate (2) · Uveitis, Posterior (2) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Giant Cell Arteritis (1) · Glaucoma (1) · Inflammation (1) · Macular Edema (1) · Ocular Hypertension (1)
Eye Diseases (7) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Uveal Diseases (5) · Choroid Diseases (3) · Genetic Diseases, Inborn (3) · Nervous System Diseases (3) · Cardiovascular Diseases (2) · Eye Diseases, Hereditary (2) · Glaucoma, Open-Angle (2) · Infant, Newborn, Diseases (2) · Iris Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Retinal Degeneration (2)
Adrenal Cortex Hormones (1) · Intravitreal Injections (1) · Latanoprost (1) · Triamcinolone (1) · Triamcinolone Acetonide (1) · aflibercept (1) · ataluren (1) · dorzolamide (1)
Clearside Biomedical, Inc. (3) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · PTC Therapeutics (1) · ProQR Therapeutics (1) · Qlaris Bio, Inc. (1) · University College, London (1)
United States (6) · Canada (2) · France (1) · Italy (1) · United Kingdom (1)
Thomas Ciulla, MD (2) · B. Wirostko, M.D. (1) · Julie Daniels (1) · Luciano Quaranta, MD (1) · Quintus Ngumah, OD, PhD (1) · Sajjad Ahmad (1) · Susan Coultas, PhD (1)
PMID 27312975, PMID 27980877, PMID 28957960, PMID 31215818, PMID 37418643, PMID 42490097
2008 (1), 2018 (1)